Pharmaceuticals

CHINARES PHARMA

China Resources Medicine Commercial Reports a 14.9% Decline in First Quarter Profit

China Resources Medicine Commercial Group Completes the Second Tranche of 2026 Corporate Bond Issuance

China Resources Medicine Sees Profit Grow to 4.05 Billion Yuan in 2025 Annual Report

Tian Dong Pharmaceutical's Naitu Heparin Calcium API Approved by NMPA

Huaron Bio-Pharmaceutical Group reported a significant decline in revenue and net profit for Q1 2026

Huahua Pharmaceutical Announces Kunyan Group's Q1 2026 Results: Revenue Decline and Net Loss

CR Pharm 华润三九 Q1 2026 Revenue 8.13B yuan, Net Profit 1.209B yuan

Tianshi Pharmaceutical 2026 Q1 Revenue and Net Profit Growth but Cash Decline

CHINA RESOURCES PHARMACEUTICAL SUB-HUANQIUSHANSEAH REPORTS DECREASE IN REVENUE AND PROFIT IN Q1 2026

Huaren Pharmaceutical's Subsidiary Kunming Beckhnothen Obtains Approval for Mycophenolic Acid Dry Suspension

SAMR Approves China Resources for Unconditional Acquisition of Beijing Aerospace Medical Company

Huaren Medicine Holdings Issues First RMB 1.5 Billion Corporate Bond

China Resources Pharmaceutical Commerce Issues RMB 1.8 Billion Corporate Bonds

CMBI Raises Forecast and Rating for China Resources Medicine

BofA Securities Raises Huaren Pharmaceutical's Performance Forecast and Target Price

China Resources Medicine Announces Yearly Performance: Revenue Up 4.6%, Profits Up 20.7%

CHINARES PHARMA released FY2025 Q3 earnings on March 24, 2026 (BJT) with actual revenue of HKD 75.27 B and EPS of HKD 0.1712

CHINARES PHARMA released FY2025 9 Months Earnings on March 24, 2026 (BJT) with actual revenue of HKD 218.05 B and EPS of HKD 0.5286

CHINARES PHARMA released FY2025 earnings on March 24 Pre-Market (BJT), actual revenue HKD 294.63 B (forecast HKD 297.74 B), actual EPS HKD 0.7032 (forecast HKD 0.612)

CHINARES PHARMA released FY2025 Q4 earnings on March 24 Pre-Market (BJT) with actual revenue HKD 0 and EPS HKD 0

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.06.17, Cash dividend 0.139 HKD

03320

China Resources Pharmaceutical Group Ltd. has completed the public issuance of RMB1.4 billion in corporate bonds for its subsidiary, China Resources Pharmaceutical Commercial Group Company Limited. The bonds have a three-year term and a coupon rate of 1.65% per annum. The proceeds will be used for production-related expenditures, including working capital replenishment, debt repayment, and project investments. This financing is expected to enhance the subsidiary's operational liquidity and support the group's growth strategy in China's pharmaceutical sector.

Tip Ranks

China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China

00068

01021

03858

06636

01773

01310

09903

02889

01057

MANYCORE TECH(00068) fell 13.76%, with a trading turnover 586.3 Million HKD, and a year-to-date rose 222.3%. HUAYAN ROBOTICS(01021) fell 12.39%, with a trading turnover 70.3 Million HKD, and a year-to-date rose 25.6%. JIAXIN INTL RES(03858) fell 11.3%, with a trading turnover 815.5 Million HKD, and a year-to-date rose 76.4%.

Top Gainers&Losers

MANYCORE TECH

HUAYAN ROBOTICS

JIAXIN INTL RES

EXTREME VISION

TIANLI INT HLDG

HKBN

ILUVATAR COREX

PATEO

ZHEJIANG SHIBAO

Top 10 HK Stock Losers (4.27)

600062

002886

China Resources Pharma's Shenzhou Biotech, a subsidiary of CR Double-Crane, has made significant breakthroughs in the industrial application of synthetic biology. The core product, 1,4-butanediamine, has been successfully integrated into WOTE's newly launched Wouper PA46 bio-based high-performance polyamide material system. This marks the entry of China Resources Pharma's products into the high-performance materials application field. Wouper PA46 boasts multiple excellent properties, making it suitable for high-end manufacturing sectors such as automotive transmission systems and precision electronics, demonstrating strong downstream application potential

AASTOCKS

CR Double-Crane

WOTE

CHINARES PHARMA introduces new product system for downstream customers under 1,4-Butanediamine

CHINARES PHARMA announced that its wholly-owned subsidiary, CHINARES PHARMA Holdings, has completed the issuance of 2026 corporate bonds (Phase I) with a principal amount of 1.5 billion RMB, a term of three years, and a coupon rate of 1.65%. The funds raised in this phase will be used for productive expenditures

CHINARES PHARMA has completed the issuance of 1.5 billion RMB corporate bonds with an interest rate of 1.65%

03750

MPNGY

BABA

The Hang Seng Index closed at 26,306 points, up 359 points or 1.4%. The Hang Seng Tech Index reported 5,058 points, up 146 points or 3.0%. Alibaba rose 4.6%, closing at HKD 134.5; CATL hit a new high, rising 10.3%, closing at HKD 723; Ganfeng Lithium rose 7.3%, closing at HKD 84.15. Other active stocks including Tencent, Meituan, and Xiaomi also saw varying degrees of increase

CATL

Meituan

Alibaba

BABA-W

TENCENT

MircroPort Medbot-B

ASMPT

GANFENGLITHIUM

Ganfeng Lithium

Direxion FTSE China Bull 3X

KraneShares 2x Long BABA Daily ETF

Hang Seng Index

Hang Seng TECH Index

Hang Seng China Enterprises Index

MEITUAN

XIAOMI-W

BIDU-SW

Baidu

HAIDILAO

NEW ORIENTAL-S

New Oriental EDU & Tech

TRIP.COM-S

Trip.com

NTES-S

NetEase

BYD COMPANY

DEEPEXI TECH

GUOXIA TECH

GUOQUAN

MARKETINGFORCE

GOFINTECH QUANT

CARSGEN-B

PONY-W

BABA-WR

Alibaba HK SDR 5to1

CATL HK SDR 30to1

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

MEITUAN-WR

Meituan HK SDR 5to1

Xiaomi Corporation

XIAOMI-WR

Xiaomi HK SDR 2to1

BIDU-SWR

Trip.com HK SDR 50to1

BYD HK SDR 10to1

BYD Company

BYD Company Limited

BYD COMPANY-R

Pony AI

The Half-Day Express reports that the Hang Seng Index rose by 359 points; the Hang Seng Tech Index increased by 146 points. Alibaba rose by over 4%, while CATL, Ganfeng Lithium, MicroPort Medbot-B, ASMPT, and CHINARES PHARMA reached new highs

03032

03088

BABX

02015

01384

06699

03067

03033

The Hang Seng Index closed at 25,907 points, up 155 points or 0.6%; the Hang Seng Tech Index reported 4,873 points, up 51 points or 1.1%. Among the active blue-chip stocks, Alibaba rose 2.8%, Meituan rose 0.9%, and Tencent fell 0.7%. Li Auto rose 4.2%, SMIC rose 3.5%, and CATL rose 3.5%. DEEPEXI TECH surged 51.8%, while different groups rose 14.9%. XunCe, ANGELALIGN, and CHINARES PHARMA all reached new highs

HSTECH ETF

CAM HS TECH

BABA 2x Long Daily ETF - GraniteShares

LI AUTO-W

ANGELALIGN

ISHARESHSTECH

CSOP HS TECH

The Half-Day Report: The Hang Seng Index closed at 25,907 points, up 155 points; the Hang Seng Tech Index closed at 4,873 points, up 51 points. Li Auto rose over 4%, while XunCe, Angelalign, and China Resources Pharma reached new highs

STECH

03692

159316

The Hang Seng Index closed at 24,624 points, down 126 points or 0.5%; the Hang Seng TECH Index reported 4,646 points, down 44 points or 0.9%. The National Index fell 70 points or 0.8%, closing at 8,328 points. Among the actively traded blue-chip stocks, HANSOH PHARMA rose over 6%, while Xiaomi, Alibaba, Meituan, and others experienced varying degrees of decline. Overall market performance was weak, with some individual stocks like BYD Electronics and Xinyi Glass seeing significant drops

HANSOH PHARMA

Bank Of China

BANK OF CHINA

ICBC

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Technology ETF(QDII)

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong Hang Seng TECH ETF(QDII)

Hang Seng TECH ETF I

Dacheng Hang Seng Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

The "Half-Day Express" reported that the Hang Seng Index closed at 24,624 points, down 126 points; the Hang Seng TECH Index closed at 4,646 points, down 44 points. HANSOH PHARMA rose over 6%, while Bank Of China, ICBC, Guangdong Investment, Guofu Quantum, and CHINARES PHARMA reached new highs

CHINARES PHARMA(03320.HK)